Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease

Annals of Neurology

Volumn 40, Issue 1, 1996, Pages 49-54

  Weeks, R A ^a   Piccini, P ^a   Harding, A E ^b   Brooks, D J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBON 11; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENETIC RISK; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MALE; MUTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING;

EID: 0029895292     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400110     Document Type: Article

References (31)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983
2. Flaherty AW, Graybiel AM. Anatomy of the basal ganglia. In: Marsden CD, Fahn S, eds. Movement disorders 3. Oxford: Butterworth-Heinemann, 1994:1-27
3. Albin RL, Young AB, Penny JB, et al. Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990;322: 1293-1298
4. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992;31:425-430
5. Strange P. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993;8:263-270
6. Surmeier DJ, Reiner A, Levine MS, et al. Are neostriatal dopamine receptors co-localised? Trends Neurosci 1993;16:299-305
7. Gerfen CR, Keefe KA. Neostriatal dopamine receptors. Trends Neurosci 1994;17:2-3
8. Bloch B, Le Moine C. Neostriatal dopamine receptors. Trends Neurosci 1994;17:3-4
9. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organisation. Trends Neurosci 1992;15:133-138
10. 2 receptor binding in patients with Huntington's disease and other choreas: a PET study. Brain 1995;118:689-696
11. Antonini A, Weindl A, Leenders KL. Brain glucose metabolism and striatal dopamine receptor density in subjects genetically at risk for Huntington's disease (HD) measured with positron emission tomography (PET). Neurology 1993;43(No. 4, Suppl 2):A335 (Abstract)
12. Davis MB, Bateman D, Quinn NP, et al. Mutation analysis in patients with possible but apparently sporadic Huntington's disease. Lancet 1994;344:714-717
13. Simpson SA, Harding AE. Predictive testing for Huntington's disease: after the gene. The United Kingdom Huntington's Disease Prediction Consortium. J Med Genet 1993;30:1036-1038
14. Spinks TJ, Jones T, Gilardi MC, et al. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Sci 1988;35:721-725
15. Spinks TJ, Tones T, Bailey D, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992;37:1637-1655
16. Robb RA, Hanson DP. A software system for interactive and quantitative analysis of biomedical images. Australas Phys Eng Sci Med 1991;14:9-30
17. Mintun MA, Raichle ME, Kilbourn MR, et al. Quantitative model fot the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227
18. 11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52
19. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age at onset in Huntington's disease. Nature Genet 1993;4:387-392
20. Vonsattel J-P, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577
21. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995;54:105-120
22. Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci USA 1988;85:5733-5737
23. 2 dopamine receptor mRNA in striatal neurons. Brain Res 1993; 621:106-110
24. Surmeier DJ, Eberwine J, Wilson CJ, et al. Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci USA 1992;89:10178-10182
25. Richfield EK, O'Brien CF, Eskin T, et al. Heterogenous dopamine receptor changes in early and late Huntington's disease. Neurosci Lett 1991;132:121-126
26. Fricker RA, Torres EM, Hume SP, et al. Functional striatal grafts: correlations between positron emission tomography in vivo, graft survival, and recovery of reaching behaviour. Soc Neurosci Abstr 1994;20:473 (Abstract)
27. Spokes EG. Neurochemical alterations in Huntington's chorea. A study of post-mortem brain tissue. Brain 1980;103:179-210
28. Bird ED, Iversen LL. Huntington's chorea-post mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 1974;97:457-472
29. Kurlan R, Goldblatt D, Zaczek R. Cerebrospinal fluid, homovanillic acid, and parkinsonism in Huntington's disease. Ann Neurol 1988;24:282-284
30. Salmon E, Brooks DJ, Leenders KL, et al. A two compartmental description and kinetic procedure for measuring regional cerebral [11C] nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab 1990;10:307-316
31. Aylward EH, Drandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994;44: 823-828